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The burden of inherited disorders of hemoglobin, the
commonest group of single gene disorders in India is
huge. With a population of 1.21 billion and an average
prevalence of b-thalassemia carriers being around 3.5-4%,
there would be 35-45 million carriers and the estimated
number of births of affected babies annually would be
10,000-12,000. The carrier rates vary from 1-17% in dif-
ferent ethnic groups. Apart from b-thalassemia, Hb E is
common in the north eastern region and in West Bengal
(4 to > 50%) and Hb S is prevalent in parts of central,
western and eastern India (5-40%). Thus interaction of
the b-thalassemias with these Hb variants is not uncom-
mon and can lead to a severe disorder.
One way to combat the burden is by prenatal diagnosis
but the only approach to reduce the national burden is
by a comprehensive community control programme.
Awareness is very limited in different states (<20%
among pregnant women) and the entire public health
infrastructure from medical colleges to district hospitals
and down to the community health centres must be
mobilized for education and generating awareness on
these disorders. Experience shows that screening for
carriers in India will have to be done at multiple levels –
schools, colleges, antenatal clinics as well as cascade
screening where extended family members of an affected
child are screened. However, antenatal screening with
subsequent testing of the husbands of carrier women
would be the most cost effective way to identify couples
at-risk and give them the option of prenatal diagnosis.
For this, obstetricians must recognize the implications of
hypochronic and microcytic red cell indices (MCV <80 fl,
MCH < 27 pg and a high RBC count) and ask for a b-tha-
lassemia screen by estimation of HbA2 levels. Several
laboratories in the country use automated HPLC for reli-
able HbA2 estimation and identification of heterozygotes
is not a problem. Late registration at antenatal clinics
(only 15-20% in the first trimester in public hospitals) is
an impediment resulting in many couples at-risk being
identified late and requiring second trimester fetal diag-
nosis. Social stigmatization is an issue to be dealt with
during premarital screening of marriage partners of car-
rier individuals. Only education can reduce this barrier.
Many State Governments in India are now undertaking
population screening and counselling programmes and
Gujarat and West Bengal have taken the lead.
There are 10-12 centres offering prenatal diagnosis by
CVS and DNA analysis and recently the Indian Council
of Medical Research has established 6 more centres in
different regions. However, many more centres would
be required once there is an increasing demand. The
spectrum of mutations and their distribution are now
known which would facilitate prenatal diagnosis.
Thus, there are many challenges – a large and diverse
population, limited awareness, late registration in
antenatal clinics and inequality of available services
(urban v/s rural areas) with around 70% of the popula-
tion residing in rural areas. There is a need for the Cen-
tral and State Governments to join hands and involve
NGO groups to form networks in different regions
which when backed by political will could gradually
reduce the national burden of hemoglobinopathies in
this vast country.
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